The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
The company has posted net profit of Rs.165.66 crores for the Financial Year ended March 31, 2022
All the capex is being met through internal accruals only
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
EDQM has also issued a Certificate of Suitability for Allopurino
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Subscribe To Our Newsletter & Stay Updated
